InBody Co Ltd

InBody maintains a strong liquidity position with a current ratio of 6.48 and cash and equivalents of KRW 52.37 billion, indicating robust short-term financial flexibility. The company's debt-to-equity ratio of 0.03 suggests a conservative capital structure, with long-term debt at KRW 10.34 billion compared to total equity of KRW 317.85 billion. Free cash flow of KRW 25.97 billion and operating cash flow of KRW 35.78 billion further support its liquidity profile. Profitability metrics show InBody outperforms the industry median in return on equity (ROE) of 9.64% and return on assets (ROA) of 8.48%. The company's gross margin of 77.4% (KRW 181.01 billion gross profit on KRW 233.95 billion revenue) and operating margin of 15.7% (KRW 36.75 billion operating income) reflect strong cost control and pricing power. Geographically, InBody's revenue is concentrated in domestic and key international markets, including the United States, China, Japan, and India. While the company's global footprint supports diversification, its exposure to a few major markets may introduce regional concentration risk. Outlook data indicates a positive growth trajectory, with revenue expected to increase in the current fiscal year and beyond. The company's capital expenditure of KRW -7.42 billion suggests a focus on optimizing existing assets rather than aggressive expansion. Risk assessment highlights low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt load and strong cash position reduce financial distress risk. However, potential dilution sources remain limited, with no recent issuance or shelf registration activity reported. Recent events include strong analyst sentiment, with a mean price target of KRW 44,000 and a mean recommendation of 1.00 (strong buy). The absence of recent filings or transcripts suggests stable operations and no immediate operational or strategic disruptions.